Compare CRNX & ENVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRNX | ENVA |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 2018 | 2011 |
| Metric | CRNX | ENVA |
|---|---|---|
| Price | $33.97 | $169.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $76.75 | ★ $185.71 |
| AVG Volume (30 Days) | ★ 1.2M | 147.3K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.05 |
| EPS | N/A | ★ 3.46 |
| Revenue | $1,039,000.00 | ★ $3,151,653,000.00 |
| Revenue This Year | $720.10 | $149.64 |
| Revenue Next Year | $184.67 | $16.42 |
| P/E Ratio | ★ N/A | $48.51 |
| Revenue Growth | N/A | ★ 18.58 |
| 52 Week Low | $25.83 | $92.75 |
| 52 Week High | $57.99 | $176.68 |
| Indicator | CRNX | ENVA |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 57.13 |
| Support Level | $33.36 | $154.76 |
| Resistance Level | $37.23 | $176.20 |
| Average True Range (ATR) | 1.36 | 5.09 |
| MACD | -0.23 | 0.16 |
| Stochastic Oscillator | 29.09 | 91.28 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.